Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice
نویسندگان
چکیده
منابع مشابه
Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice
The aim of this study was to investigate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. The study was performed using the monoclonal antibody MX35 F(ab')(2) labeled with the alpha-particle emitter (211)At. Methods. Nude mice were intraperitoneally inoculated with ~1 x 10(7) cells of the cell line NIH:OVCAR-3. Four ...
متن کاملIntraperitoneal radioimmunotherapy for ovarian cancer.
Twenty-eight patients with assessable residual ovarian cancer after cytoreductive surgery and chemotherapy received intraperitoneal I-131 labelled monoclonal antibodies. There was no response in eight patients with tumour nodules greater than 2 cm, a partial response in two of the 15 patients with tumour nodules less than 2 cm, and a complete response in three of the other five patients with po...
متن کاملIntraperitoneal Radioimmunotherapy for Ovarian Cancer
Purpose: The purpose of this study was to determine the feasibility and maximum tolerated dose of Yttrium-CC49 (Y-CC49) as the radioimmunotherapy (RIT) component of an i.p. combined modality treatment for recurrent ovarian cancer. Experimental Design: A Phase I trial of Y-CC49 RIT was conducted in ovarian cancer patients who had persistent or recurrent intra-abdominal disease, had failed one or...
متن کاملIntraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities
Background The aim of this study was to investigate the therapeutic efficacy of advanced ovarian cancer in mice, using α-radioimmunotherapy with different high specific activities. The study was performed using the monoclonal antibody (mAb) MX35 F(ab')2 labeled with the α-particle emitter 211At. Methods Animals were intraperitoneally inoculated with ≥1 × 107 cells of the ovarian cancer cell l...
متن کاملBrief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
Due to the generally slow and incomplete transit of i.p. infused agents into the circulation, treating disease confined to the peritoneal cavity with chemotherapy, biologics, and/or radionuclides provides a pharmacologic advantage. A higher i.p. concentration can be achieved than could be tolerated by systemic administration. An advantage of i.p. versus i.v. administration for localization of r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Oncology
سال: 2010
ISSN: 1687-8450,1687-8469
DOI: 10.1155/2010/394913